{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:18:23Z","timestamp":1791584303444,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jval.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T07:34:13Z","timestamp":1713339253000},"page":"1149-1173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review"],"prefix":"10.1016","volume":"27","author":[{"given":"Kednapa","family":"Thavorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Rose","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srishti","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliisa","family":"Heiskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubhav","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Hawrysh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Kar-Wing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Presseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Ollendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy M.","family":"Grimshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Mathew","family":"Lalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surapon","family":"Nochaiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Kekre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib1","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","article-title":"Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia","volume":"6","author":"Grover","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2024.04.004_bib4","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Clin Oncol Educ Book"},{"key":"10.1016\/j.jval.2024.04.004_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CEOR.S241880","article-title":"Cost-effectiveness analysis of tisagenlecleucel in the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in children and young adults in Spain","volume":"12","author":"Ribera Santasusana","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.jval.2024.04.004_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.jval.2024.04.004_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13427","article-title":"Cost-effectiveness of anti-CD19 chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. A societal view","volume":"105","author":"Thielen","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jval.2024.04.004_bib8","doi-asserted-by":"crossref","first-page":"241.e1","DOI":"10.1016\/j.jtct.2020.12.023","article-title":"Cost-effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in Japan","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jval.2024.04.004_bib9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jval.2024.04.004_bib10","article-title":"Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy for Treating Large B-Cell Lymphoma Patients in Canada","author":"Ellis","year":"2019","journal-title":"Master\u2019s Thesis. University of Waterloo"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib11","first-page":"458","article-title":"Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States","volume":"24","author":"Liu","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.jval.2024.04.004_bib12","first-page":"1238","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"2","key":"10.1016\/j.jval.2024.04.004_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14737167.2019.1651646","article-title":"Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy","volume":"19","author":"Petrou","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737167.2023.2214731","article-title":"Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update","volume":"23","author":"Petrou","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jval.2021.07.008","article-title":"A\u00a0systematic review of health technology assessments of chimeric antigen receptor T-cell therapies in young compared with older patients","volume":"25","author":"Gye","year":"2022","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2024.04.004_bib17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jcyt.2023.05.011","article-title":"A\u00a0systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R\/R B-ALL) treatment in children and young adults","volume":"25","author":"Andrade","year":"2023","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jval.2024.04.004_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14737167.2016.1246962","article-title":"How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development","volume":"16","author":"Thielen","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14737167.2016.1246960","article-title":"How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach","volume":"16","author":"van Mastrigt","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/14737167.2016.1246961","article-title":"How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability","volume":"16","author":"Wijnen","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.jval.2024.04.004_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"36","key":"10.1016\/j.jval.2024.04.004_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2024.04.004_bib26","series-title":"Developing NICE Guidelines: The Manual","first-page":"140","article-title":"Incorporating economic evaluation","author":"National Institute for Health and Care","year":"2022"},{"issue":"9","key":"10.1016\/j.jval.2024.04.004_bib29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","article-title":"Adjusting for inflation and currency changes within health economic studies","volume":"22","author":"Turner","year":"2019","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2024.04.004_bib30","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3390\/curroncol29030164","article-title":"Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed\/Refractory Mantle Cell Lymphoma following Treatment with a bruton's tyrosine kinase Inhibitor in Canada","volume":"29","author":"Ball","year":"2022","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.jval.2024.04.004_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/cancers14030538","article-title":"Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed\/Refractory Diffuse Large B-cell Lymphoma in Spain","volume":"14","author":"Bastos-Oreiro","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib32","article-title":"Cost-utility and value of information analysis of tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma in the Irish healthcare setting","volume":"11","author":"Carey","year":"2023","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib33","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462322000356","article-title":"Tisagenlecleucel for relapsed\/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis","volume":"38","author":"Carey","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"10.1016\/j.jval.2024.04.004_bib34","first-page":"1321","article-title":"Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore\u2019s healthcare system perspective","volume":"23","author":"Cher","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.jval.2024.04.004_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45956","article-title":"Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"5","author":"Choe","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.jval.2024.04.004_bib36","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1007\/s12325-022-02188-0","article-title":"Cost-effectiveness of chimeric antigen receptor T cell therapy in patients with relapsed or refractory large B cell lymphoma: no impact of site of care","volume":"39","author":"Cummings","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jval.2024.04.004_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40273-022-01188-w","article-title":"Cost-effectiveness analysis of tisagenlecleucel versus Blinatumomab in children and young adults with acute lymphoblastic leukemia: partitioned survival model to assess the impact of an outcome-based payment arrangement","volume":"41","author":"Gye","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2024.04.004_bib38","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40273-022-01169-z","article-title":"The cost effectiveness of axicabtagene Ciloleucel versus Best supportive care in the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy in Canada","volume":"40","author":"Hillis","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"19","key":"10.1016\/j.jval.2024.04.004_bib39","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2022016747","article-title":"Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Kambhampati","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jval.2024.04.004_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221142945","article-title":"Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma","volume":"30","author":"Kapinos","year":"2023","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib41","first-page":"243","article-title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed\/refractory multiple myeloma patients in Canada and France","volume":"26","author":"Karampampa","year":"2023","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2024.04.004_bib42","author":"Lee"},{"key":"10.1016\/j.jval.2024.04.004_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231168215","article-title":"Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States","volume":"14","author":"Li","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"10.1016\/j.jval.2024.04.004_bib44","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1007\/s00520-022-07041-2","article-title":"Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China","volume":"30","author":"Li","year":"2022","journal-title":"Support Care Cancer"},{"issue":"32","key":"10.1016\/j.jval.2024.04.004_bib45","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.jval.2024.04.004_bib46","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2024.04.004_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.vhri.2023.03.006","article-title":"Cost-effectiveness analysis of relmacabtagene autoleucel for relapsed or refractory large B-cell lymphoma in China","volume":"37","author":"Lin","year":"2023","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib48","first-page":"1303","article-title":"Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","volume":"26","author":"Loftager","year":"2023","journal-title":"J\u00a0Med Econ"},{"issue":"8","key":"10.1016\/j.jval.2024.04.004_bib49","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1080\/10428194.2023.2215888","article-title":"Cost-Effectiveness of brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma","volume":"64","author":"Marchetti","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib50","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s12325-021-01767-x","article-title":"Cost-effectiveness of tisagenlecleucel in paediatric acute lymphoblastic leukaemia (pALL) and adult diffuse large B-cell lymphoma (DLBCL) in Switzerland","volume":"38","author":"Moradi-Lakeh","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib51","first-page":"541","article-title":"Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US","volume":"25","author":"Oluwole","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib52","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s12325-023-02444-x","article-title":"Cost-effectiveness of lisocabtagene Maraleucel versus Axicabtagene ciloleucel and tisagenlecleucel in the third-line or later treatment setting for relapsed or refractory large B-cell lymphoma in the United States","volume":"40","author":"Parker","year":"2023","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.jval.2024.04.004_bib53","doi-asserted-by":"crossref","first-page":"750.e1","DOI":"10.1016\/j.jtct.2022.08.010","article-title":"The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib54","first-page":"730","article-title":"Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed\/refractory mantle cell lymphoma post BTKi in England","volume":"25","author":"Petersohn","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib55","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jval.2024.04.004_bib56","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.clinthera.2021.06.011","article-title":"Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States","volume":"43","author":"Qi","year":"2021","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.jval.2024.04.004_bib57","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1007\/s12325-022-02201-6","article-title":"Cost-effectiveness of KTE-X19 for adults with relapsed\/refractory B-cell acute lymphoblastic leukemia in the United States","volume":"39","author":"Shah","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib58","first-page":"421","article-title":"Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States","volume":"24","author":"Simons","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib59","doi-asserted-by":"crossref","first-page":"506.e1","DOI":"10.1016\/j.jtct.2021.03.005","article-title":"Cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma in Japan","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib60","first-page":"637","article-title":"Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore\u2019s private insurance payer\u2019s perspective","volume":"24","author":"Wang","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2024.04.004_bib61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEOR.S355557","article-title":"Cost-effectiveness and budget impact analyses of tisagenlecleucel in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia from the Singapore healthcare system perspective","volume":"14","author":"Wang","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib62","first-page":"701","article-title":"Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma in China","volume":"26","author":"Wu","year":"2023","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib63","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40258-023-00817-5","article-title":"Value for money of CAR-T cell therapy for patients with diffuse large B-cell lymphoma in China: evidence from a cost-effectiveness analysis","volume":"21","author":"Wu","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"10.1016\/j.jval.2024.04.004_bib64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","article-title":"Cost-effectiveness of Tisagenlecleucel vs Standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada","volume":"6","author":"Furzer","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12962-022-00400-0","article-title":"Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier","volume":"20","author":"Jakobs","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib66","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/ejh.14095","article-title":"Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach","volume":"111","author":"Kurte","year":"2023","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib67","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10637-023-01389-w","article-title":"Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-cell therapies for treatment of relapsed or refractory follicular lymphoma","volume":"41","author":"Ghanem","year":"2023","journal-title":"Investig New Drugs"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jval.2024.04.004_bib69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jval.2024.04.004_bib70","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"John","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"26","key":"10.1016\/j.jval.2024.04.004_bib72","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2024.04.004_bib73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jval.2024.04.004_bib74","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"10.1016\/j.jval.2024.04.004_bib75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-statistics-031017-100101","article-title":"Cure models in survival analysis","volume":"5","author":"Amico","year":"2018","journal-title":"Annu Rev Stat Its Appl"},{"issue":"3","key":"10.1016\/j.jval.2024.04.004_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2014.03.1130","article-title":"The inherent bias from using partitioned survival models in economic evaluation","volume":"17","author":"Coyle","year":"2014","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib78","first-page":"630","article-title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","volume":"19","author":"Goeree","year":"2016","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.jval.2024.04.004_bib79","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","article-title":"Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes","volume":"38","author":"Smare","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2024.04.004_bib81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0272989X17697019","article-title":"Extrapolation of survival data in cost-effectiveness analyses: the need for causal clarity","volume":"37","author":"Hawkins","year":"2017","journal-title":"Med Decis Mak"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib82","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","volume":"8","author":"Jorgensen","year":"2020","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2024.04.004_bib83","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jval.2024.04.004_bib84","article-title":"Industry sponsorship bias in cost effectiveness analysis: registry based analysis","volume":"377","author":"Xie","year":"2022","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib85","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task Force-1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2024.04.004_bib86","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jval.2024.04.004_bib87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2024.04.004_bib88","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jval.2024.04.004_bib89","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/bcp.14275","article-title":"A\u00a0systematic review of economic evaluations of advanced therapy medicinal products","volume":"87","author":"Lloyd-Williams","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jval.2024.04.004_bib90","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.19.01558","article-title":"Valuing chimeric antigen receptor T-cell therapy: current evidence, uncertainties, and payment implications","volume":"38","author":"Whittington","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T14:23:43Z","timestamp":1722522223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524023362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1098301524023362"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}